Table 1 Summary of clinical trials describing HDAC and DNMT inhibitors in combination with immune checkpoint blockade therapy [130]
From: Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Clinical trial identifier | Status | Phase | Cancer type | Epigenetic drug | Immune checkpoint inhibitor | Additional intervention |
|---|---|---|---|---|---|---|
NCT02635061 | Not yet recruiting | I | Unresectable NSCLC | ACY-241 | Nivolumab and ipilimumab | Â |
NCT01686165 | Not yet recruiting | II | DLBCL | Belinostat | Rituximab | Yttrium-90 |
NCT02453620 | Recruiting | I | Metastatic unresectable HER2-negative breast cancer | Entinostat | Nivolumab and ipilimumab | Â |
NCT02909452 | Recruiting | I | Advanced solid tumours | Entinostat | Pembrolizumab | Â |
NCT03024437 | Not yet recruiting | I/II | Advanced cell carcinoma | Entinostat | Atezolizumab | Bevacizumab |
NCT02708680 | Recruiting | I/II | Breast cancer | Entinostat | Atezolizumab | Â |
NCT02697630 | Recruiting | II | Metastatic uveal melanoma | Entinostat | Prembrolizumab | Â |
NCT02805660 | Recruiting | I/II | Advanced solid tumours and NSCLC | Mocetinostat | Durvalumab | Â |
NCT02437136 | Recruiting | I/II | NSCLC and melanoma | Entinostat | Pembrolizumab | Â |
NCT02993991 | Not yet recruiting | I | Squamus cell carcinoma of the oral cavity | Mocetinostat | Durvalumab | Â |
NCT02032810 | Recruiting | I | Unresectable stage III/IV melanoma | Panobinostat | Ipilimumab | Â |
NCT01238692 | Not yet recruiting | II | DLBCL | Panobinostat | Rituximab | Â |
NCT01282476 | Not yet recruiting | II | DLBCL | Panobinostat | Rituximab | Â |
NCT02512172 | Recruiting | I | Advanced CRC | Romidepsin and/or 5-AZA | Pembrolizumab | Â |
NCT02538510 | Recruiting | I/II | HNSCC and SGC | Vorinostat | Pembrolizumab | Â |
NCT02638090 | Recruiting | I/II | Stage IV NSCLC | Vorinostat | Pembrolizumab | Â |
NCT02619253 | Recruiting | I/II | Advanced renal or urothelial cell carcinoma | Vorinostat | Pembrolizumab | Â |
NCT02395627 | Recruiting | II | Hormone therapy-resistant breast cancer | Vorinostat | Pembrolizumab | Tamoxifen |
NCT00667615 | Not yet recruiting | I/II | DLBCL | Vorinostat | Rituximab | Cyclophosphamide, etoposide, prednisone |
NCT00720876 | Not yet recruiting | II | Lymphoma | Vorinostat | Rituximab | Â |
NCT00972478 | Not yet recruiting | I/II | DLBCL | Vorinostat | Rituximab | Cyclophosphamide, doxorubicin, prednisone, vincristin |
NCT00764517 | Not recruiting | II | Lymphoma | Vorinostat | Rituximab | Cladribine |
NCT00918723 | Not yet recruiting | I | Lymphoma/leukaemia | Vorinostat | Rituximab | Cyclophosphamide, fludarabine |
NCT02397720 | Recruiting | II | AML | 5-AZA | Nivolumab | Â |
NCT02260440 | Recruiting | II | Metastatic CRC | 5-AZA | Pembrolizumab | Â |
NCT02546986 | Recruiting | II | Advanced/metastatic NSCLC | 5-AZA | Pembrolizumab | Â |
NCT02508870 | Recruiting | I | MDS | 5-AZA | Atezolizumab | Â |
NCT02951156 | Not yet recruiting | II | DLBCL | 5-AZA | Rituximab | Bendamustine, gemcitabine, oxaliplatin |
NCT02530463 | Recruiting | II | MDS | 5-AZA | Nivolumab and/or ipilimumab | Â |
NCT02399917 | Recruiting | II | Refractory/relapsed AML | 5-AZA | Lirilumab | Â |
NCT02599649 | Recruiting | II | MDS | 5-AZA | Lirilumab and nivolumab | Â |
NCT02512172 | Recruiting | I | MSS advanced CRC | Romidepsin and/or 5-AZA | Pembrolizumab | Â |
NCT02816021 | Not yet recruiting | II | Metastatic melanoma | 5-AZA | Pembrolizumab | Â |
NCT01928576 | Recruiting | I | NSCLC | 5-AZA and/or entinostat | Nivolumab | Â |
NCT02795923 | Not yet recruiting | II | NSCLC | 5-AZA-CdR/tetrahydrouridine | Nivolumab | Â |
NCT02811497 | Recruiting | II | Advanced solid tumours | 5-AZA | Durvalumab | Â |